PAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: Implications for the treatment of negative symptoms in schizophrenia

Schizophrenia Research

Volumn 125, Issue 1, 2011, Pages 88-92

  Dyck, Bailee ^a   Guest, Kelly ^a   Sookram, Christal ^a   Basu, Dipannita ^a   Johnson, Rodney ^b   Mishra, Ram K ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Dopamine D2 receptor; MK 801; Non competitive NMDA antagonist; PAOPA; Social interaction

Indexed keywords

3 [(2 PYRROLIDYNLCARBONYL)AMINO] 2 OXO 1 PYRROLIDINEACETAMIDE; BRAIN PEPTIDE; DIZOCILPINE; DOPAMINE 2 RECEPTOR; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; MALE; NEGATIVE SYNDROME; NONHUMAN; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; RAT; SCHIZOPHRENIA; SOCIAL BEHAVIOR; SOCIAL INTERACTION;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DRUG ADMINISTRATION SCHEDULE; INTERPERSONAL RELATIONS; MALE; MSH RELEASE-INHIBITING HORMONE; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; SOCIAL BEHAVIOR DISORDERS;

EID: 78650264988     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.09.025     Document Type: Article

References (44)

1. Bast T., Zhang W., Feldon J., White I.M. Effects of MK801 and neuroleptics on prepulse inhibition: re-examination in two strains of rats. Pharmacol. Biochem. Behav. 2000, 67:647-658.
2. BELL D.S. Comparison of amphetamine psychosis and schizophrenia. Br. J. Psychiatry 1965, 111:701-707.
3. Benkert O., Muller-Siecheneder F., Wetzel H. Dopamine agonists in schizophrenia: a review. Eur. Neuropsychopharmacol. 1995, 5(Suppl):43-53.
4. Blin O. A comparative review of new antipsychotics. Can. J. Psychiatry 1999, 44:235-244.
5. Castellano J.M., Batrynchuk J., Dolbeare K., Verma V., Mann A., Skoblenick K.J., Johnson R.L., Mishra R.K. MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats. Peptides 2007, 28:2009-2015.
6. Chiu S., Paulose C.S., Mishra R.K. Neuroleptic drug-induced dopamine receptor supersensitivity: antagonism by l-prolyl-l-leucyl-glycinamide. Science 1981, 214:1261-1262.
7. Chiu S., Wong Y.W., Wan Y.P., Chiu P., Mishra R.K. Are the pharmacological effects of l-prolyl-l-leucyl-glycinamide (PLG) mediated through specific receptor mechanisms?. Prog. Neuropsychopharmacol. Biol. Psychiatry 1983, 7:739-742.
8. Crow T.J. Positive and negative schizophrenic symptoms and the role of dopamine. Br. J. Psychiatry 1980, 137:383-386.
9. Farber N.B. The NMDA receptor hypofunction model of psychosis. Ann. NY Acad. Sci. 2003, 1003:119-130.
10. File S.E. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J. Neurosci. Methods 1980, 2:219-238.
11. Guo N., Guo W., Kralikova M., Jiang M., Schieren I., Narendran R., Slifstein M., Abi-Dargham A., Laruelle M., Javitch J.A., Rayport S. Impact of d2 receptor internalization on binding affinity of neuroimaging radiotracers. Neuropsychopharmacology 2010, 35:806-817.
12. Guy A.P., Gardner C.R. Pharmacological characterisation of a modified social interaction model of anxiety in the rat. Neuropsychobiology 1985, 13:194-200.
13. Jentsch J.D., Taylor J.R., Roth R.H. Subchronic phenylcyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology 1998, 19(2):105-113.
14. Johnson R.L., Rajakumar G., Mishra R.K. Dopamine receptor modulation by Pro-Leu-Gly-NH2 analogues possessing cyclic amino acid residues at the C-terminal position. J. Med. Chem. 1986, 29:2100-2104.
15. Kapur S., Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2) receptors-implications for models of schizophrenia. Mol. Psychiatry 2002, 7:837-844.
16. Lahti A.C., Weiler M.A., Tamara Michaelidis B.A., Parwani A., Tamminga C.A. Effects of Ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001, 25(4):455-467.
17. Laruelle M., Kegeles L.S., Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann. NY Acad. Sci. 2003, 1003:138-158.
18. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., Grace A.A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008, 31:234-242.
19. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997, 17:141-150.
20. Manahan-Vaughan D., von Haebler D., Winter C., Juckel G., Heinemann U. A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats. Hippocampus 2008, 18:125-134.
21. Mishra R.K. Modulation of CNS dopamine receptors by peptides. Prog. Neuropsychopharmacol. Biol. Psychiatry 1983, 7:437-442.
22. Mishra R.K., Chiu S., Chiu P., Mishra C.P. Pharmacology of l-prolyl-l-leucyl-glycinamide (PLG): a review. Meth. Find Exp. Clin. Pharmacol. 1983, 5:203-233.
23. Mishra R.K., Srivastava L.K., Johnson R.L. Modulation of high-affinity CNS dopamine D2 receptor by lpro-l-leu-glycinamide (PLG) analogue 3(R)-(N-l-prolylamino)-2-oxo-1-pyrrolidineacetamide. Prog. Neuropsychopharmacol. Biol. Psychiatry 1990, 14:821-827.
24. Mishra R.K., Marcotte E.R., Chugh A., Barlas C., Whan D., Johnson R.L. Modulation of dopamine receptor agonist-induced rotational behavior in 6-OHDA-lesioned rats by a peptidomimetic analogue of Pro-Leu-Gly-NH2 (PLG). Peptides 1997, 18:1209-1215.
25. Namkung Y., Dipace C., Javitch J.A., Sibley D.R. G protein-coupled receptor kinase-mediated phosphorylation regulates post-endocytic trafficking of the D2 dopamine receptor. J. Biol. Chem. 2009, 284:15038-15051.
26. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 2004, 72:29-39.
27. Olbrich R., Schanz H. The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics. Pharmacopsychiatry 1988, 21:389-390.
28. Ott M.C., Mishra R.K., Johnson R.L. Modulation of dopaminergic neurotransmission in the 6-hydroxydopamine lesioned rotational model by peptidomimetic analogues of l-prolyl-l-leucyl-glycinamide. Brain Res. 1996, 737:287-291.
29. Raghavan B., Skoblenick K.J., Bhagwanth S., Argintaru N., Mishra R.K., Johnson R.L. Allosteric modulation of the dopamine D2 receptor by Pro-Leu-Gly-NH2 peptidomimetics constrained in either a polyproline II helix or a type II beta-turn conformation. J. Med. Chem. 2009, 52:2043-2051.
30. Rung J.P., Carlsson A., Ryden M.K., Carlsson M.L. (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:827-832.
31. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav. Pharmacol. 1996, 7:3-23.
32. Sams-Dodd F. Effects of continuous d-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 1998, 19:18-25.
33. Sams-Dodd F. (+) MK-801 and phencyclidine induced neurotoxicity do not cause enduring behaviours resembling the positive and negative symptoms of schizophrenia in the rat. Basic Clin. Pharmacol. Toxicol. 2004, 95:241-246.
34. Sharma S., Paladino P., Gabriele J., Saeedi H., Henry P., Chang M., Mishra R.K., Johnson R.L. Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: a model of human tardive dyskinesia. Peptides 2003, 24:313-319.
35. Siegel R.K. Phencyclidine and ketamine intoxication: a study of four populations of recreational users. NIDA Res. Monogr. 1978, 119-147.
36. Skinbjerg M., Namkung Y., Halldin C., Innis R.B., Sibley D.R. Pharmacological characterization of 2-methoxy-N-propylnorapomorphine's interactions with D2 and D3 dopamine receptors. Synapse 2009, 63:462-475.
37. Smith J.R., Morgan M. The effects of prolyl-leucyl-glycine amide on drug-induced rotation in lesioned rats. Gen. Pharmacol. 1982, 13:203-207.
38. Snigdha S., Neill J.C. Efficiency of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats - a preliminary investigation. Behav. Brain Res. 2008, 187(2):489-494.
39. Snyder S.H. Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines. Am. J. Psychiatry 1973, 130:61-67.
40. Srivastava L.K., Bajwa S.B., Johnson R.L., Mishra R.K. Interaction of l-prolyl-l-leucyl glycinamide with dopamine D2 receptor: evidence for modulation of agonist affinity states in bovine striatal membranes. J. Neurochem. 1988, 50:960-968.
41. Stefani M.R., Moghaddam B. Transient N-methyl-d-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol. Psychiatry 2005, 57:433-436.
42. Verma V., Mann A., Costain W., Pontoriero G., Castellano J.M., Skoblenick K., Gupta S.K., Pristupa Z., Niznik H.B., Johnson R.L., Nair V.D., Mishra R.K. Modulation of agonist binding to human dopamine receptor subtypes by l-prolyl-l-leucyl-glycinamide and a peptidomimetic analog. J. Pharmacol. Exp. Ther. 2005, 315:1228-1236.
43. Wetzel H., Hillert A., Grunder G., Benkert O. Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms. Am. J. Psychiatry 1994, 151:1499-1502.
44. Yu K.L., Rajakumar G., Srivastava L.K., Mishra R.K., Johnson R.L. Dopamine receptor modulation by conformationally constrained analogues of Pro-Leu-Gly-NH2. J. Med. Chem. 1988, 31:1430-1436.